Zobrazeno 1 - 10
of 1 851
pro vyhledávání: '"Brossart, P."'
Autor:
Michael Praktiknjo, Ana S. Pena Solano, Farsaneh Sadeghlar, Thomas Welchowski, Matthias Schmid, Christian Möhring, Taotao Zhou, Robert Mahn, Malte B. Monin, Carsten Meyer, Georg Feldmann, Peter Brossart, Cornelius van Beekum, Alexander Semaan, Hanno Matthaei, Steffen Manekeller, Alois M. Sprinkart, Sebastian Nowak, Julian Luetkens, Jörg C. Kalff, Christian P. Strassburg, Maria A. González-Carmona
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this
Externí odkaz:
https://doaj.org/article/e8b3f61e90fe4943b829122cfda08c0d
Autor:
Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTObjectives The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous
Externí odkaz:
https://doaj.org/article/29275ba759c143408d4a11bc8678e7fb
Autor:
Rebekka Mispelbaum, Tessa Hattenhauer, Franz-Georg Bauernfeind, Jan-Frederic Lau, Peter Brossart, Annkristin Heine
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In the setting of metastatic adrenocortical cancer, there are limited therapy options such as mitotane and platinum-based chemotherapy with only low response rates. Ipilimumab and nivolumab are approved for several solid cancer types. Tumor mutationa
Externí odkaz:
https://doaj.org/article/da2771142a4841c2a2ee8d6f51af0ae3
Autor:
Mahn R, Glüer OA, Sadeghlar F, Möhring C, Zhou T, Anhalt T, Monin MB, Kania A, Glowka TR, Feldmann G, Brossart P, Kalff JC, Schmidt-Wolf IGH, Strassburg CP, Gonzalez-Carmona MA
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 81-94 (2024)
Robert Mahn,1,* Oscar André Glüer,1,* Farsaneh Sadeghlar,1 Christian Möhring,1 Taotao Zhou,1 Thomas Anhalt,1 Malte Benedikt Monin,1 Alexander Kania,2 Tim R Glowka,2 Georg Feldmann,3 Peter Brossart,3 Joerg C Kalff,2 Ingo GH Schmidt-Wolf,4 C
Externí odkaz:
https://doaj.org/article/7b0e6b47d2314e87ba683eca85fb6ff5
Autor:
Milka Marinova, David-Alexis Khouri, Jim Küppers, Olga Ramig, Holger M. Strunk, Johannes Breuers, Julia Fazaal, Christine Fuhrmann, Martin Coenen, Christian Möhring, Taotao Zhou, Xin Zhou, Thomas Anhalt, Farsaneh Sadeghlar, Marcus Thudium, Rupert Conrad, Georg Feldmann, Peter Brossart, Tim R. Glowka, Jörg C. Kalff, Markus Essler, Christian P. Strassburg, Yon-Dschun Ko, Ingo G. H. Schmidt-Wolf, Maria Gonzalez-Carmona
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 13, p 3717 (2024)
Background: Pancreatic adenocarcinoma (PaC) still has a dismal prognosis, and despite medical advances, a bleak 5-year survival rate of only 8%, largely due to late diagnosis and limited curative surgical options for most patients. Frontline palliati
Externí odkaz:
https://doaj.org/article/7a4d5305890f40fda7bc1c01b83c7dd3
Autor:
Xuan Wang, Johanna Breuer, Stephan Garbe, Frank Giordano, Peter Brossart, Georg Feldmann, Savita Bisht
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 11, p 6249 (2024)
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of human malignancies and carries an exceptionally poor prognosis. It is mostly driven by multiple oncogenic alterations, with the highest mutation frequency being observed in the KRAS g
Externí odkaz:
https://doaj.org/article/e99fb62d73e0465ca8235051f74d62b6
Autor:
Friederike Hoffmann, Alina Franzen, Luka de Vos, Lennert Wuest, Zsófi Kulcsár, Simon Fietz, Alexander Philippe Maas, Sarah Hollick, Marie Yatou Diop, Jennis Gabrielpillai, Timo Vogt, Pia Kuster, Romina Zarbl, Joern Dietrich, Glen Kristiansen, Peter Brossart, Jennifer Landsberg, Sebastian Strieth, Dimo Dietrich
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-13 (2023)
Abstract Background The majority of patients with recurrent or metastasized head and neck squamous cell carcinoma (HNSCC) do not benefit from immune checkpoint blockade (ICB) while several patients experience severe and persistent immune-mediated sid
Externí odkaz:
https://doaj.org/article/2828807dfb384e6996689ecfb93a477e
Autor:
Stephanie Andersen, Annalee Wilson, Todd Combs, Laura Brossart, Julie Heidbreder, Stacey McCrary, Rinad S. Beidas, Leopoldo J. Cabassa, Erin P. Finley, Emma E. McGinty, Jonathan Purtle, Lisa Saldana, Enola Proctor, Douglas Luke
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
Abstract Introduction: Demonstrating the impact of implementation science presents a new frontier for the field, and operationalizing downstream impact is challenging. The Translational Science Benefits Model (TSBM) offers a new approach for assessi
Externí odkaz:
https://doaj.org/article/b2e37fddc3d34e1ea71b50ab02713d5f
Publikováno v:
Case Reports in Hematology, Vol 2024 (2024)
T-prolymphocytic leukaemia (T-PLL) is the most common mature T-cell leukaemia in Central Europe and is often manifested by rapidly increasing lymphocytosis, marked bone marrow infiltration and splenomegaly. In 10–15% of cases, the diagnosis is made
Externí odkaz:
https://doaj.org/article/acfc12b1bcbe4822831dfd4bd85568e7
Autor:
Annkristin Heine, Niels A. W. Lemmermann, Chrystel Flores, Janine Becker-Gotot, Natalio Garbi, Peter Brossart, Christian Kurts
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionProphylactic vaccines generate strong and durable immunity to avoid future infections, whereas post-exposure vaccinations are intended to establish rapid protection against already ongoing infections. Antiviral cytotoxic CD8+ T cells (CTL
Externí odkaz:
https://doaj.org/article/051e31edb5824e1484a74bf513adbdb8